UroGen Pharma to Present at Upcoming Investor Conferences
30 Janvier 2025 - 2:00PM
Business Wire
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
participate at the following investor conferences in February:
Guggenheim Securities SMID Cap Biotech Conference
Date / Time:
February 5, 2025 at 10:30 AM ET
Format:
Presentation and 1x1 investor meetings
Location:
New York, NY
Webcast Link:
here
Oppenheimer 35th Annual Healthcare Life Sciences
Conference
Date / Time:
February 11, 2025 at 1:20 PM ET
Format:
Presentation and 1x1 investor meetings
Location:
Virtual
Webcast Link:
here
Webcasts from the conferences will also be available on UroGen’s
Investor Relations website. A replay will be available on the site
for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained-release, hydrogel-based platform technology that has the
potential to improve the therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Our first
product to treat LG-UTUC and investigational treatment UGN-102
(mitomycin) for intravesical solution for patients with low-grade
non-muscle invasive bladder cancer are designed to ablate tumors by
non-surgical means. UroGen is headquartered in Princeton, NJ with
operations in Israel. Visit www.UroGen.com to learn more or follow
us on X (Twitter), @UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250130241788/en/
INVESTORS: Vincent Perrone Senior Director, Investor Relations
vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA: Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma (NASDAQ:URGN)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
UroGen Pharma (NASDAQ:URGN)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
